Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 1/2021

Open Access 01-02-2021 | Anticoagulant | Research Article

Evaluation of patients’ knowledge about oral anticoagulant medicines and use of alert cards by community pharmacists

Authors: Yogini H. Jani, Bindiya Hirani, Carina Livingstone

Published in: International Journal of Clinical Pharmacy | Issue 1/2021

Login to get access

Abstract

Background Anticoagulants continue to pose high risk of harm to patients despite the discovery of novel direct-acting oral anticoagulant agents that require less monitoring than warfarin. Objective To evaluate patients’ knowledge about their oral anticoagulants and the potential role for community pharmacists in optimising safety. Setting Community pharmacies in England. Methods An online survey-based evaluation conducted over a 5-month period to ascertain patients’ knowledge, use of anticoagulant alert cards, compliance with national monitoring requirements for warfarin, and frequency and nature of community pharmacist involvement in optimisation. Differences between patients on direct-acting oral anticoagulant agents and warfarin were assessed using Chi squared tests. Main outcome measure Patients’ knowledge and use of anticoagulant alert cards. Results A total of 1515 pharmacies participated. Of 22,624 patients, 97% knew that they were taking anticoagulants; 20% had alert cards with them at time of dispensing; 17% had no card and 10% refuted their usefulness. Patients on warfarin were more aware of interactions with over-the-counter or herbal medicines than those on direct-acting oral anticoagulant agents. Of the patients on warfarin, 82% confirmed monitoring in the previous 12 weeks in accordance with national standards, with the international normalised ratio value known for 76%. Pharmacists intervened in a fifth of the patients to issue an alert card, contact the general practitioner for a change in the prescription or due to interacting medicines. Conclusion Patients had reasonable knowledge of their anticoagulation therapy, but areas for improvement were identified. Community pharmacists are well placed to optimise the safe use of anticoagulants.
Literature
5.
go back to reference Hawes EM. Patient education on oral anticoagulation. Pharmacy (Basel). 2018;6(2):34.CrossRef Hawes EM. Patient education on oral anticoagulation. Pharmacy (Basel). 2018;6(2):34.CrossRef
6.
go back to reference Tang EO, Lai CS, Lee KK, Wong RS, Cheng G, Chan TY. Relationship between patients’ warfarin knowledge and anticoagulation control. Ann Pharmacother. 2003;37(1):34–9.CrossRef Tang EO, Lai CS, Lee KK, Wong RS, Cheng G, Chan TY. Relationship between patients’ warfarin knowledge and anticoagulation control. Ann Pharmacother. 2003;37(1):34–9.CrossRef
7.
go back to reference Ko H, Turner T, Jones C, Hill C. Patient-held medical records for patients with chronic disease: a systematic review. Qual Saf Health Care. 2010;19(5):e41.PubMed Ko H, Turner T, Jones C, Hill C. Patient-held medical records for patients with chronic disease: a systematic review. Qual Saf Health Care. 2010;19(5):e41.PubMed
9.
go back to reference Stafford L, Peterson GM, Bereznicki LR, Jackson SL, van Tienen EC, Angley MT, et al. Clinical outcomes of a collaborative, home-based postdischarge warfarin management service. Ann Pharmacother. 2011;45(3):325–34.CrossRef Stafford L, Peterson GM, Bereznicki LR, Jackson SL, van Tienen EC, Angley MT, et al. Clinical outcomes of a collaborative, home-based postdischarge warfarin management service. Ann Pharmacother. 2011;45(3):325–34.CrossRef
10.
go back to reference Stafford L, van Tienen EC, Bereznicki LR, Peterson GM. The benefits of pharmacist-delivered warfarin education in the home. Int J Pharm Pract. 2012;20(6):384–9.CrossRef Stafford L, van Tienen EC, Bereznicki LR, Peterson GM. The benefits of pharmacist-delivered warfarin education in the home. Int J Pharm Pract. 2012;20(6):384–9.CrossRef
11.
go back to reference MacFarlane BV, Bergin JK, Reeves P, Matthews A. Australian pharmacies prevent potential adverse reactions in patients taking warfarin requesting over-the-counter analgesia. Int J Pharm Pract. 2015;23(3):167–72.CrossRef MacFarlane BV, Bergin JK, Reeves P, Matthews A. Australian pharmacies prevent potential adverse reactions in patients taking warfarin requesting over-the-counter analgesia. Int J Pharm Pract. 2015;23(3):167–72.CrossRef
12.
go back to reference Harrison J, Shaw JP, Harrison JE. Anticoagulation management by community pharmacists in New Zealand: an evaluation of a collaborative model in primary care. Int J Pharm Pract. 2015;23(3):173–81.CrossRef Harrison J, Shaw JP, Harrison JE. Anticoagulation management by community pharmacists in New Zealand: an evaluation of a collaborative model in primary care. Int J Pharm Pract. 2015;23(3):173–81.CrossRef
13.
go back to reference Ingram SJ, Kirkdale CL, Williams S, Hartley E, Wintle S, Sefton V, et al. Moving anticoagulation initiation and monitoring services into the community: evaluation of the Brighton and hove community pharmacy service. BMC Health Serv Res. 2018;18(1):91.CrossRef Ingram SJ, Kirkdale CL, Williams S, Hartley E, Wintle S, Sefton V, et al. Moving anticoagulation initiation and monitoring services into the community: evaluation of the Brighton and hove community pharmacy service. BMC Health Serv Res. 2018;18(1):91.CrossRef
14.
go back to reference Community Pharmacy NSAID Safety Audit. England: NHS Specialist Pharmacy Service; 2014. Community Pharmacy NSAID Safety Audit. England: NHS Specialist Pharmacy Service; 2014.
17.
go back to reference PSNC. Clinical governance requirements for community pharmacy London: NHS Employers; 2012. PSNC. Clinical governance requirements for community pharmacy London: NHS Employers; 2012.
19.
go back to reference National Community Pharmacy Oral Anticoagulant Safety Audit. England: NHS Specialist Pharmacy Service; 2018. www.sps.nhs.uk. Accessed April 2020. National Community Pharmacy Oral Anticoagulant Safety Audit. England: NHS Specialist Pharmacy Service; 2018. www.​sps.​nhs.​uk. Accessed April 2020.
20.
go back to reference Konieczyńska M, Sobieraj E, Bryk AH, Dębski M, Polak M, Podolec P, et al. Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists. Kardiol Pol. 76. Poland2018. p. 1089–96. Konieczyńska M, Sobieraj E, Bryk AH, Dębski M, Polak M, Podolec P, et al. Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists. Kardiol Pol. 76. Poland2018. p. 1089–96.
21.
go back to reference Hernández Madrid A, Potpara TS, Dagres N, Chen J, Larsen TB, Estner H, et al. Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a self-assessment patient survey conducted by the European Heart Rhythm Association. Europace. 2016;18(3):463–7.CrossRef Hernández Madrid A, Potpara TS, Dagres N, Chen J, Larsen TB, Estner H, et al. Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a self-assessment patient survey conducted by the European Heart Rhythm Association. Europace. 2016;18(3):463–7.CrossRef
22.
go back to reference Berdi F, Tadlaoui Y, Fahry A, Zbir M, Bennana A, Bousliman Y. CP-188 Evaluation of patient’s knowledge about vitamin K antagonist treatment. Eur J Hosp Pharm. 2017;24(Suppl 1):A84-A. Berdi F, Tadlaoui Y, Fahry A, Zbir M, Bennana A, Bousliman Y. CP-188 Evaluation of patient’s knowledge about vitamin K antagonist treatment. Eur J Hosp Pharm. 2017;24(Suppl 1):A84-A.
23.
go back to reference Palareti G, Legnani C, Guazzaloca G, Lelia V, Cosmi B, Lunghi B, et al. Risks factors for highly unstable response to oral anticoagulation: a case-control study. Br J Haematol. 2005;129(1):72–8.CrossRef Palareti G, Legnani C, Guazzaloca G, Lelia V, Cosmi B, Lunghi B, et al. Risks factors for highly unstable response to oral anticoagulation: a case-control study. Br J Haematol. 2005;129(1):72–8.CrossRef
24.
go back to reference Obamiro KO, Chalmers L, Bereznicki LR. Development and Validation of an Oral Anticoagulation Knowledge Tool (AKT). PLoS ONE. 2016;11(6):e0158071.CrossRef Obamiro KO, Chalmers L, Bereznicki LR. Development and Validation of an Oral Anticoagulation Knowledge Tool (AKT). PLoS ONE. 2016;11(6):e0158071.CrossRef
27.
go back to reference Hamedi N, da Costa FA, Horne R, Levitan M, Begley A, Antoniou S. How prepared are pharmacists to support atrial fibrillation patients in adhering to newly prescribed oral anticoagulants? Int J Clin Pharm. 2017;39(6):1273–81.CrossRef Hamedi N, da Costa FA, Horne R, Levitan M, Begley A, Antoniou S. How prepared are pharmacists to support atrial fibrillation patients in adhering to newly prescribed oral anticoagulants? Int J Clin Pharm. 2017;39(6):1273–81.CrossRef
28.
go back to reference Papastergiou J, Kheir N, Ladova K, Rydant S, De Rango F, Antoniou S, et al. Pharmacists’ confidence when providing pharmaceutical care on anticoagulants, a multinational survey. Int J Clin Pharm. 2017;39(6):1282–90.CrossRef Papastergiou J, Kheir N, Ladova K, Rydant S, De Rango F, Antoniou S, et al. Pharmacists’ confidence when providing pharmaceutical care on anticoagulants, a multinational survey. Int J Clin Pharm. 2017;39(6):1282–90.CrossRef
31.
go back to reference Robertson SG, Glass BD. Stability of repackaged dabigatran etexilate capsules in dose administration aids. Eur J Hosp Pharm. 2018;25(e2):e93.CrossRef Robertson SG, Glass BD. Stability of repackaged dabigatran etexilate capsules in dose administration aids. Eur J Hosp Pharm. 2018;25(e2):e93.CrossRef
Metadata
Title
Evaluation of patients’ knowledge about oral anticoagulant medicines and use of alert cards by community pharmacists
Authors
Yogini H. Jani
Bindiya Hirani
Carina Livingstone
Publication date
01-02-2021
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 1/2021
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-020-01134-w

Other articles of this Issue 1/2021

International Journal of Clinical Pharmacy 1/2021 Go to the issue